Skip to content

Music news, business and culture.

Join Newsletter

Israel’s BioLineRx Sells APHEXDA Royalty Rights for $5.6 Million

Israel's BioLineRx has agreed to sell part of its future APHEXDA royalty payments to Soleus Capital for a one-time payment of US$5.6 million.

BioLineRx Ltd. and Soleus Capital

BioLineRx Ltd. has agreed to sell a share of its future royalty payments from APHEXDA (motixafortide) to Soleus Capital for a one-time payment of US$5.6 million. The deal provides non-dilutive capital, meaning funding that does not involve issuing new shares.

Deal terms#

  • Soleus will acquire BioLineRx’s 14.4% royalty interest in future net sales of APHEXDA under the company’s license agreement with Ayrmid Pharma Ltd. (Ayrmid).
  • A separate 3.6% royalty interest, attributable to the original licensor of motixafortide to BioLineRx, is excluded from the sale and stays with that licensor.
  • BioLineRx keeps its rights to potential commercial milestone payments under the Ayrmid agreement.
  • BioLineRx also keeps royalty payments tied to periods before the transaction closes.
  • The transaction is expected to close on or about November 30, 2026.

Philip Serlin, Chief Executive Officer of BioLineRx, said: “This transaction enables us to immediately unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial milestone payments.”

Serlin added: “Importantly, the non-dilutive capital will provide additional financial flexibility as we continue to advance our lead development asset, GLIX1, through its ongoing Phase 1/2a clinical trial in glioblastoma and other solid tumors. We believe this transaction represents an attractive, non-dilutive financing solution for our company and our shareholders.”

Benjamin Lund, Partner at Soleus Capital, said: “We are pleased to partner with BioLineRx on this transaction, which provides us with an opportunity to participate in the future commercial performance of APHEXDA. We believe APHEXDA represents a differentiated treatment option in stem cell mobilization for patients with multiple myeloma, and we look forward to supporting BioLineRx through this innovative financing arrangement.”

Planned use of proceeds#

BioLineRx intends to use the proceeds for research and development, including the clinical development of GLIX1, as well as for working capital and general corporate purposes. Part of the funds will go toward a partial repayment of a loan from BlackRock EMEA Venture and Growth Lending.

The partial repayment also eliminates the company’s minimum cash balance requirement under the loan agreement, which is currently $4 million.

APHEXDA and GLIX1 background#

APHEXDA is a CXCR4 antagonist approved by the U.S. Food and Drug Administration (FDA) for use with filgrastim (granulocyte colony-stimulating factor, or G-CSF) to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent autologous stem cell transplantation in patients with multiple myeloma. Ayrmid commercializes the drug globally except in Asia, where it is partnered with Gloria Biosciences.

GLIX1 is BioLineRx’s lead development asset, a first-in-class, oral, small molecule targeting the DNA damage response in glioblastoma and other solid tumors. Its Phase 1/2a clinical trial began in the first quarter of 2026 and is currently enrolling the fourth of five planned dosing cohorts. GLIX1 is being developed in collaboration with Hemispherian AS.

BioLineRx also holds rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and is running a Phase 2b PDAC trial in collaboration with Columbia University. The company’s shares trade on NASDAQ and the Tel Aviv Stock Exchange (TASE).

About Soleus Capital#

Soleus Capital is an investment firm based in Greenwich, Connecticut, in the United States, focused on life sciences, including biopharmaceuticals, medical technologies, life sciences tools and diagnostics. As of June 30, 2026, it had approximately $3.5 billion in total assets under management. The firm invests across the healthcare lifecycle, from developmental-stage to commercial companies, and works with life science companies across the capital structure through hedge fund, private equity and structured credit vehicles.

Sponsored

ToneGrid: deliver your music globally. White-label distribution, royalties and analytics for labels and distributors.

More like this

Pick your tempo

Who owns what, who got paid, and who is about to. The business behind African music, told like it is actually interesting (because it is).

  • The deals and catalogue sales nobody put out a press release for
  • Chart moves and streaming numbers we actually fact-checked (wild, we know)
  • Fresh names added to the directory, vetted before you ever see them

Free forever Ghost us anytime, one click

Get the inside track from Afrobeats Wire

Choose your speed. We will handle the rest.

How fast do you want it?

Your inbox is sacred. This address is used for the newsletter and nothing else, never sold, never passed on. Privacy policy.